Docetaxel

Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
30021
Randomized phase II trial of Docetaxel (Taxotere) and Oblimersen vs Taxotere alone in patients with HRPC
10003
An EORTC-BG-IDBBC/ECSG phase II study evaluating the role of the multi-drug resistance (MDR) reversor, R101933, in patients with taxane refractory metastatic breast cancer.
24981
A feasibility study of primary chemotherapy followed by concomitant chemoradiation with or without amifostine in patients with locally advanced undifferenciated nasopharyngeal cancer (UNPC).
55961
EORTC 55961,Phase II study on Paclitaxel in recurrent uterine papillary serous carcinoma (UPSC)
55985
PHASE II CLINICAL TRIAL ON TAXOL AS SINGLE AGENT IN LOCALLY ADVANCED AND/OR METASTATIC OR RECURRENT VULVA CANCER NOT AMENABLE FOR SURGERY AND/OR RADIOTHERAPY - EORTC trial 55985
08012
Pre-operative chemotherapy in resectable NSCLC. Randomised trial of surgical resection with or without pre-operative chemotherapy in patients with operable non small cell lung cancer (NSCLC) of any stage.
10994
First prospective Intergroup Translational Research Trial assessing the potential predictive value of p53 using a functional assay in yeast in patients with locally advanced/inflammatory or large operable breast cancer prospectively randomised to a taxane versus a non taxane regimen.
10054
A phase I-II study of Lapatinib and Docetaxel as neoadjuvant treatment for locally advanced breast cancer.
10041
MINDACT (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid Chemo Therapy): A prospective, randomized study comparing the 70-gene signature with the common clinicpathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes"
24061
Randomized phase II feasibility study of Cetuximab combined with 4 cycles of TPF followed by platinum based chemo-radiation strategies
24051
Phase I/II study on induction chemotherapy followed by chemoradiation with or without lapatinib, a dual EGFR/ErbB2 kinase inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell.

Back to Protocol section